Cytek Biosciences, Inc.
DE ˙ DB ˙ US23285D1090
3,46 € ↓ -0,08 (-2,26%)
2026-06-04
AKTIENPREIS
SecurityDE:8EQ / Cytek Biosciences, Inc.
InstitutionMillennium Management Llc
ManagerIsrael Englander
Latest Disclosed Ownership7,872,900 shares
Ownership 6.10%
Millennium Management Llc ownership in 8EQ / Cytek Biosciences, Inc.

2026-05-18 - Millennium Management Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 7,872,900 shares of Cytek Biosciences, Inc. (DE:8EQ). This represents 6.1 percent ownership of the company. In their previous filing dated 2026-04-09 , Millennium Management Llc had reported owning 6,638,827 shares, indicating an increase of 18.59 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-05-18 2026-05-18 13G/A 6,638,827 7,872,900 18.59 6.10 17.31
2026-04-09 2026-04-09 13G 6,638,827 5.20

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CYTEK BIOSCIENCES COM 23285D109 6,291,798 1,539,351 32.39 27,495 14.57 0.0114
2026-02-17 2025-12-31 13F CYTEK BIOSCIENCES COM 23285D109 4,752,447 1,334,065 39.03 24,000 102.34 0.0101
2025-11-14 2025-09-30 13F CYTEK BIOSCIENCES COM 23285D109 3,418,382 2,493,610 269.65 11,862 277.26 0.0051
2025-08-14 2025-06-30 13F CYTEK BIOSCIENCES COM 23285D109 924,772 429,335 86.66 3,144 58.31 0.0015
2025-05-15 2025-03-31 13F CYTEK BIOSCIENCES COM 23285D109 495,437 -308,486 -38.37 1,987 -61.93 0.0011
2025-02-14 2024-12-31 13F CYTEK BIOSCIENCES COM 23285D109 803,923 613,314 321.77 5,217 394.50 0.0025
2024-11-14 2024-09-30 13F CYTEK BIOSCIENCES COM 23285D109 190,609 -755,881 -79.86 1,056 -80.02 0.0005
2024-08-14 2024-06-30 13F CYTEK BIOSCIENCES COM 23285D109 946,490 919,845 3,452.22 5,281 2,866.85 0.0024
2024-05-15 2024-03-31 13F CYTEK BIOSCIENCES COM 23285D109 26,645 26,645 179 0.0001
2024-02-14 2023-12-31 13F CYTEK BIOSCIENCES COM 23285D109 0 -427,954 -100.00 0 -100.00
2023-11-14 2023-09-30 13F CYTEK BIOSCIENCES COM 23285D109 427,954 -152,049 -26.22 2,362 -52.31 0.0012
2023-08-14 2023-06-30 13F CYTEK BIOSCIENCES COM 23285D109 580,003 -372,172 -39.09 4,953 -43.39 0.0024
2023-05-15 2023-03-31 13F CYTEK BIOSCIENCES COM 23285D109 952,175 817,445 606.73 8,750 535.90 0.0050
2023-02-14 2022-12-31 13F CYTEK BIOSCIENCES COM 23285D109 134,730 -273,729 -67.02 1,376 -77.12 0.0008
2022-11-14 2022-09-30 13F CYTEK BIOSCIENCES COM 23285D109 408,459 -494,023 -54.74 6,013 -37.91 0.0036
2022-08-15 2022-06-30 13F CYTEK BIOSCIENCES COM 23285D109 902,482 784,708 666.28 9,684 662.52 0.0060
2022-05-16 2022-03-31 13F CYTEK BIOSCIENCES COM 23285D109 117,774 117,774 1,270 0.0007
2022-02-14 2021-12-31 13F CYTEK BIOSCIENCES COM 23285D109 0 -178,978 -100.00 0 -100.00
2021-11-15 2021-09-30 13F CYTEK BIOSCIENCES COM 23285D109 178,978 178,978 3,832 0.0023
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.